NEW HYDE PARK, N.Y., Jan. 12, 2026 (GLOBE NEWSWIRE) -- CareMed (R) , an independent specialty pharmacy, has been selected as a pharmacy partner by Cytokinetics for MYQORZO (TM) (aficamten), indicated ...
CareMed®, an independent specialty pharmacy, has been selected as a pharmacy partner by Cytokinetics for MYQORZO™ (aficamten), indicated for the treatment of adults with symptomatic obstructive ...
A long-awaited study commissioned by the FDA has muddied the path forward on how to reduce racial bias in pulse oximeter ...
Volume analysis examines how the number of traded shares affects a security's price. Discover how this method is integral to ...
Maduro’s arrest puts Venezuela’s vast oil reserves in focus, raising questions over control, sanctions and prospects for ...
Sciencing on MSN
What are dishwasher pods actually made of?
For many people, detergent pods are the new normal for doing their laundry, but what are they made of, and should we be ...
Cytokinetics, Incorporated's (CYTK) shares surged 40.4% on Sept. 2, driven by positive results from a phase III study on cardiovascular candidate aficamten. On Aug. 30, Cytokinetics presented primary ...
During a medical event on Saturday, Cytokinetics (NASDAQ:CYTK) announced primary results from its Phase 3 MAPLE-HCM trial for lead asset aficamten in symptomatic obstructive hypertrophic ...
(RTTNews) - Cytokinetics, Incorporated (CYTK), Tuesday announced positive topline results from Phase 3 MAPLE-HCM study of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy ...
The U.S. Food and Drug Administration (FDA) on Thursday extended the Prescription Drug User Fee Act (PDUFA) action date for the New Drug Application (NDA) for Cytokinetics Inc's (NASDAQ:CYTK) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback